biosimilar drugs

Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
FDA clears second Remicade biosimilarIn what is expected to produce hefty saving for rheumatoid arthritis patients and the healthcare system, FDA approved the second biosimilar to Remicade (Johnson & Johnson).
CVS: Generics and Biosimilars Are Key to Its Drug Spending DeclineDrug spending is going down at CVS Caremark. Here’s why.
Top challenges likely to slow adoption of biosimilarsBiosimilars will reshape clinical care and managed care pharmacy but ambiguities in the regulatory landscape and knowledge gaps among clinicians seem likely slow adoption.
What’s in the Specialty Pharmacy Pipeline?
What’s in the Specialty Pharmacy Pipeline?Biosimilars, cancer drugs, and orphan drugs are heading towards FDA approval in 2017.
Business Group Makes Price Recommendations for Specialty Drugs
Business Group Makes Price Recommendations for Specialty DrugsThe high cost of specialty drugs demands a change in Washington, according to a report.
How New Biosimilars Will Impact the MarketMore biosimilars are coming onto the market , including competitors for Remicade and Neulasta.
New diabetes medications help address linked diseasesExperts share updates on new diabetes medications, and provide an overview of what’s coming.
Are payers optimistic about biosimilars’ savings?As more biosimilars are approved, plans and PBMs will continue to evolve their strategies regarding coverage and formulary management of these new medications.
Breast cancer biosimilar shows equivalency to brand
Breast cancer biosimilar shows equivalency to brandTwo new major studies on a biosimilar to trastuzumab (Herceptin, Genentech) to treat HER2-positive metastatic breast cancer and HER2-positive gastric cancer demonstrated equivalency.